Cargando…

Pharmacotherapy of mild cognitive impairment

Amnestic mild cognitive impairment (MCI) can be considered as a state with a high risk of developing Alzheimer's disease within 5 years, or as a prodromal stage of this condition. Randomized clinical trials comparing the acetylcholinesterase inhibitor donepezil with placebo have shown some symp...

Descripción completa

Detalles Bibliográficos
Autor principal: Gauthier, Serge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Les Laboratoires Servier 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181817/
https://www.ncbi.nlm.nih.gov/pubmed/22034396
_version_ 1782212818999705600
author Gauthier, Serge
author_facet Gauthier, Serge
author_sort Gauthier, Serge
collection PubMed
description Amnestic mild cognitive impairment (MCI) can be considered as a state with a high risk of developing Alzheimer's disease within 5 years, or as a prodromal stage of this condition. Randomized clinical trials comparing the acetylcholinesterase inhibitor donepezil with placebo have shown some symptomatic benefit on (i) cognition in one short-term (6-month) study; and (ii)conversion to dementia in one long-term (3-year) study, but not for the full duration of the study, except in subjects with the apolipoprotein E4 (APOE-4) mutation, in whoom the benefit was sustained throughout the 3 years. Results from studies on galantamine are still being analyzed; and a rivastigmine study will close in the fall of 2004. It is premature to recommend that acetylcholinesterase inhibitors be used systematically in amnestic MCI. However, important lessons have been learned from studies in this prodromal stage of AD, allowing the testing of hypotheses for disease modification.
format Online
Article
Text
id pubmed-3181817
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher Les Laboratoires Servier
record_format MEDLINE/PubMed
spelling pubmed-31818172011-10-27 Pharmacotherapy of mild cognitive impairment Gauthier, Serge Dialogues Clin Neurosci Pharmacological Aspects Amnestic mild cognitive impairment (MCI) can be considered as a state with a high risk of developing Alzheimer's disease within 5 years, or as a prodromal stage of this condition. Randomized clinical trials comparing the acetylcholinesterase inhibitor donepezil with placebo have shown some symptomatic benefit on (i) cognition in one short-term (6-month) study; and (ii)conversion to dementia in one long-term (3-year) study, but not for the full duration of the study, except in subjects with the apolipoprotein E4 (APOE-4) mutation, in whoom the benefit was sustained throughout the 3 years. Results from studies on galantamine are still being analyzed; and a rivastigmine study will close in the fall of 2004. It is premature to recommend that acetylcholinesterase inhibitors be used systematically in amnestic MCI. However, important lessons have been learned from studies in this prodromal stage of AD, allowing the testing of hypotheses for disease modification. Les Laboratoires Servier 2004-12 /pmc/articles/PMC3181817/ /pubmed/22034396 Text en Copyright: © 2004 LLS http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Pharmacological Aspects
Gauthier, Serge
Pharmacotherapy of mild cognitive impairment
title Pharmacotherapy of mild cognitive impairment
title_full Pharmacotherapy of mild cognitive impairment
title_fullStr Pharmacotherapy of mild cognitive impairment
title_full_unstemmed Pharmacotherapy of mild cognitive impairment
title_short Pharmacotherapy of mild cognitive impairment
title_sort pharmacotherapy of mild cognitive impairment
topic Pharmacological Aspects
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181817/
https://www.ncbi.nlm.nih.gov/pubmed/22034396
work_keys_str_mv AT gauthierserge pharmacotherapyofmildcognitiveimpairment